[CAS NO. 884650-98-0] Mpro inhibitor N3
PRODUCTS SPECIFICATIONS [884650-98-0]
DESCRIPTION [884650-98-0]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 680.79 |
| Molecular Formula | C35H48N6O8 |
| SMILES | O=C([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](C)NC(C1=NOC(C)=C1)=O)=O)=O)N[C@H](/C=C/C(OCC2=CC=CC=C2)=O)C[C@H](CCN3)C3=O |
Summary
In Vitro
Mpro inhibitor N3 (0-100 µM) shows antiviral activities with an EC
50
value of 16.77 µM for SARS-CoV-2
[1]
.
Mpro inhibitor N3 (0-50 µM; 14 h) inhibits the viral growth with the IC
50
values of 4, 8.8, 2.7 µM for HCoV-229E, FIPV, IBV and MHV-A59, respectively
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Mpro inhibitor N3 (0-0.64 µM; 3, 6 h) shows antiviral activity against IBV in chicken , embryos [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Chicken embryos [3] |
| Dosage: | 0-0.64 µM |
| Administration: | 3, 6 h with 100-EID50 titer of IBV M41 virus |
| Result: | Showed that N3 is able to penetrate cells to inhibit the replication of IBV viruses, probably at the beginning of infection, with the PD 50 of 0.13 μmol for the 3-h group and 0.17 μmol for the 6-h group. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
DMSO : 20 mg/mL ( 29.38 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.4689 mL | 7.3444 mL | 14.6888 mL |
| 5 mM | 0.2938 mL | 1.4689 mL | 2.9378 mL |
| 10 mM | 0.1469 mL | 0.7344 mL | 1.4689 mL |
References
- [1] Jin Z, et al. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020 Jun;582(7811):289-293.
- [2] Yang H, et al. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 2005 Oct;3(10):e324.
- [3] Xue X, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008 Mar;82(5):2515-27.